Update · pages 103–109
Pharmacotherapy of Dyslipidemia: An Overview of New Cholesterol Treatment Guidelines
Cite this article
The Big Statin Debate. - Puneeta Gupta, Anil K. Gupta, R P Kudyar, Rajesh Gupta. Pharmacotherapy of Dyslipidemia: An Overview of New Cholesterol Treatment Guidelines. J Int Med Sci Acad. 2016;29(2):103–109.
Opening of the article
Numerous pathological, epidemiological, genetic and interventional trials have validated the central tenet of the lipid hypothesis, which proposes a causal relationship between dyslipidaemia and atherogenesis and identifies lipid modification as a risk reducing strategy for coronary heart disease (CHD). In 1984, National Institute of Health (NIH), Coronary Primary Prevention Trial, an NIH Consensus Conference convened concluded that lowering elevated LDL cholesterol with diet and drugs would reduce the risk of CHD.